Reply to comment on “Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study”
Reply to comment on “Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study”. // American Journal of Transplantation. – URL: https://www.sciencedirect.com/science/article/pii/S1600613526026316?dgcid=rss_sd_all
Reply to comment on “Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study”. American Journal of Transplantation. https://www.sciencedirect.com/science/article/pii/S1600613526026316?dgcid=rss_sd_all
“Reply to comment on “Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study”.” American Journal of Transplantation.
@article{article97390,
title = {Reply to comment on “Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study”},
journal = {American Journal of Transplantation},
url = {https://www.sciencedirect.com/science/article/pii/S1600613526026316?dgcid=rss_sd_all}
}